Drug Trial Radar · NCT03781934
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
Last checked: Nov 20, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Sep 5, 2018
Primary completion
Jan 7, 2025
Study completion Jun 16, 2025
Sponsor
- Lead sponsor
- MedivirIndustry
- Sponsor type
- Industry
- First posted
- Dec 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicentre dose escalation/expansion study to assess safety and tolerability of MIV 818 as either monotherapy or in combination with 1) lenvatinib, a tyrosine kinase inhibitor used as a standard of care for the treatment of HCC or 2) pembrolizumab, a PD-1 inhibitor. The monotherapy parts of the study will include patients with various solid tumours that have spread to the liver, or alternatively originating in the liver. Evaluations of MIV-818 in combination with lenvatinib or pembrolizumab will only include patients with HCC.
Conditions
- Hepatocellular Carcinoma
- Intrahepatic Cholangiocarcinoma
- Liver Metastases
Interventions
MIV-818 (fostroxacitabine bralpamide) + pembrolizumabDrug
MIV-818 - oral capsules; pembrolizumab - IV
MIV-818 (fostroxacitabine bralpamide) + lenvatinibDrug
MIV-818 - oral capsules; lenvatinib - oral capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Adverse Events (AEs)Time frame: Participants monitored throughout treatment period and during follow-up, up to 6 months
- Incidence and magnitude of clinically significant changes in red blood cell count, white blood cell count and platelet countTime frame: Participants monitored throughout treatment period and during follow-up, up to 6 months
- Incidence and magnitude of clinically significant changes in aspartate aminotransferase (AST) and alanine aminotransferase (ALT)Time frame: Participants monitored throughout treatment period and during follow-up, up to 6 months
- Incidence and magnitude of clinically significant changes in bilirubinTime frame: Participants monitored throughout treatment period and during follow-up, up to 6 months
- Incidence of clinically significant changes in vital sign - Systolic and diastolic blood pressureTime frame: Participants monitored throughout treatment period and during follow-up, up to 6 months
- Incidence of clinically significant changes in vital sign - Pulse rateTime frame: Participants monitored throughout treatment period and during follow-up, up to 6 months
- Incidence of clinically significant changes in vital sign - Body TemperatureTime frame: Participants monitored throughout treatment period and during follow-up, up to 6 months
- Incidence of clinically significant changes in vital signs - WeightTime frame: Participants monitored throughout treatment period and during follow-up, up to 6 months
- Incidence of clinically significant changes in ECGsTime frame: Participants monitored throughout treatment period and during follow-up, up to 6 months
Locations
18 sites in 4 countries. Site status is shown where the registry gives one.
Antwerp University Hospital
Antwerp, Belgium
University Hospitals Gasthuisberg
Leuven, Belgium
CHA Bundang Medical Center
Gyeonggi-do, South Korea
Pusan National University Hospital
Pusan, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea
Hospital Clinic Carrer Rosselló 161
Barcelona, Spain
Hospital Vall Hebrón
Barcelona, Spain
START Barcelona HM Nou Delfos
Barcelona, Spain
Hospital General Universitario Gregorio Marañón
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
START Madrid-FJD
Madrid, Spain
Beatson West of Scotland Cancer Care
Glasgow, United Kingdom
Guy's Hospital, Oncology and Clinical Trials
London, United Kingdom
Northern Institute for Cancer Research
Newcastle upon Tyne, United Kingdom
Chruchill Hospital, Cancer and Haematology Centre
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.